Evotec SEXSWX:EVT +4.02%68 PS Ratio is 1.15 as of Jun. 28, 2026, which is 83% below its 10-year median of 6.68. GuruFocus rates XSWX:EVT with a GF Score™ of 68/100 and a GF Value™ of CHF6.99 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 949 Drug Manufacturers companies, Evotec SE ranks better than 70.71% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Evotec SE's share price is CHF4.50.
Evotec SE's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF3.90. Hence, Evotec SE's PS Ratio for today is 1.15.
The historical rank and industry rank for Evotec SE's PS Ratio or its related term are showing as below:
XSWX:EVT'
s PS Ratio Range Over the Past 10 Years
Min: 0.94 Med: 6.68 Max: 14.34
Current: 1.17
During the past 13 years, Evotec SE's highest PS Ratio was 14.34. The lowest was 0.94. And the median was 6.68.
XSWX:EVT's PS Ratio is ranked better than 70.71% of 949
companies
in the Drug Manufacturers industry
Industry Median: 2.2
vs XSWX:EVT: 1.17
Evotec SE's Revenue per Sharefor the
three
months ended in Mar. 2026 was CHF0.80.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF3.90.
Warning Sign:
Evotec SE revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Evotec SE was -5.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 1.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 6.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 16.60% per year.
During the past 13 years, Evotec SE's highest 3-Year average Revenue per Share Growth Rate was 40.00% per year. The lowest was -30.40% per year. And the median was 12.20% per year.
Back to Basics: PS Ratio
Evotec SE (XSWX:EVT) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Evotec SE PS Ratio Related Terms
Evotec SE PS Ratio Historical Data
* Premium members only.
The historical data trend for Evotec SE's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's PS Ratio distribution charts can be found below:
* The bar in red indicates where Evotec SE's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Evotec SE's Share Price of today is CHF4.50. Evotec SE's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF3.90.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Evotec SE (XSWX:EVT) has a PS Ratio of 1.15 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Evotec SE and its competitors. This is 83% below median its historical median of 6.68. Over the past decade, Evotec SE's PS Ratio has ranged from 0.94 to 14.34. According to the industry distribution chart, Evotec SE ranks #278 out of 949 companies in the Drug Manufacturers industry, placing it in the top 29.3%.
Is Evotec SE's PS Ratio too high?
Evotec SE's current PS Ratio of 1.15 is 83% below median its 10-year median of 6.68. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 14.34. The Drug Manufacturers industry median PS Ratio is 2.20. Evotec SE's value of 1.15 is 47.7% below this industry median. Based on the distribution chart, Evotec SE ranks #278 out of 949 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Evotec SE has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #278 out of 949 companies for PS Ratio. This puts Evotec SE in the upper half of its industry. The industry median PS Ratio is 2.20. Evotec SE's value of 1.15 is 47.7% below this benchmark. Historically, Evotec SE's own PS Ratio has ranged from 0.94 to 14.34 over the past decade. While the company's 10-year median is 6.68 vs. the industry median of 2.20, Evotec SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.20, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evotec SE's current PS Ratio of 1.15 is 47.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current PS Ratio is 1.15, which is 83% below median its own 10-year median of 6.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (XSWX:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is CHF6.99, compared to a current price of CHF4.50 — trading 35.6% below its estimated fair value. The current PS Ratio is 1.15, which is 83% below median its 10-year median of 6.68 and 47.7% below the Drug Manufacturers industry median of 2.20. Evotec SE's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current PS Ratio is 1.15 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (XSWX:EVT) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of CHF4.50 is trading 35.6% below its estimated GF Value™ of CHF6.99.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for XSWX:EVT:
PS Ratio: 1.15 (83% below median its 10-year median of 6.68)
GF Value™: CHF6.99 vs. price of CHF4.50 (35.6% below fair value)
Industry Position: 47.7% below the Drug Manufacturers median (#278 of 949)
No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
68GF Score
Get the complete analysis for XSWX:EVT
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EVT has been successfully added to your 
